China Medical System Holdings Limited (0867.HK)
0867.HK Stock Price Chart
Explore China Medical System Holdings Limited interactive price chart. Choose custom timeframes to analyze 0867.HK price movements and trends.
0867.HK Company Profile
Discover essential business fundamentals and corporate details for China Medical System Holdings Limited (0867.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
28 Sept 2010
Employees
6.14K
Website
https://www.cms.net.cnCEO
Kong Lam
Description
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
0867.HK Financial Timeline
Browse a chronological timeline of China Medical System Holdings Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 16 Mar 2026
Dividend declared on 29 Aug 2025
A dividend of $0.17 per share was announced, adjusted to $0.17. The dividend will be paid on 9 Sept 2025.
Earnings released on 18 Aug 2025
EPS came in at $0.43 surpassing the estimated $0.41 by +5.20%, while revenue for the quarter reached $4.39B , beating expectations by +0.02%.
Dividend declared on 28 Apr 2025
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend was paid on 9 May 2025.
Earnings released on 17 Mar 2025
EPS came in at $0.31 falling short of the estimated $0.36 by -14.09%, while revenue for the quarter reached $4.10B , missing expectations by -5.16%.
Dividend declared on 29 Aug 2024
A dividend of $0.16 per share was announced, adjusted to $0.16. The dividend was paid on 9 Sept 2024.
Earnings released on 15 Aug 2024
EPS came in at $0.40 surpassing the estimated $0.34 by +16.64%, while revenue for the quarter reached $3.88B , missing expectations by -1.67%.
Dividend declared on 13 May 2024
A dividend of $0.09 per share was announced, adjusted to $0.09. The dividend was paid on 23 May 2024.
Earnings released on 27 Mar 2024
EPS came in at $0.22 falling short of the estimated $0.59 by -63.54%, while revenue for the quarter reached $3.77B , missing expectations by -57.04%.
Dividend declared on 11 Sept 2023
A dividend of $0.34 per share was announced, adjusted to $0.34. The dividend was paid on 20 Sept 2023.
Earnings released on 28 Aug 2023
EPS came in at $0.85 surpassing the estimated $0.78 by +8.87%, while revenue for the quarter reached $4.99B , missing expectations by -6.32%.
Dividend declared on 3 May 2023
A dividend of $0.27 per share was announced, adjusted to $0.27. The dividend was paid on 12 May 2023.
Earnings released on 17 Mar 2023
EPS came in at $0.68 falling short of the estimated $0.71 by -4.91%, while revenue for the quarter reached $5.36B , missing expectations by -49.04%.
Dividend declared on 5 Sept 2022
A dividend of $0.34 per share was announced, adjusted to $0.34. The dividend was paid on 15 Sept 2022.
Earnings released on 23 Aug 2022
EPS came in at $0.86 falling short of the estimated $0.87 by -1.04%, while revenue for the quarter reached $5.21B , beating expectations by +0.28%.
Dividend declared on 26 Apr 2022
A dividend of $0.28 per share was announced, adjusted to $0.28. The dividend was paid on 6 May 2022.
Earnings released on 14 Mar 2022
EPS came in at $0.69 surpassing the estimated $0.69 by +0.44%, while revenue for the quarter reached $5.50B , beating expectations by +3.88%.
Dividend declared on 6 Sept 2021
A dividend of $0.32 per share was announced, adjusted to $0.32. The dividend was paid on 15 Sept 2021.
Earnings released on 30 Jun 2021
EPS came in at $0.79 surpassing the estimated $0.73 by +7.91%, while revenue for the quarter reached $4.61B , missing expectations by -6.36%.
Dividend declared on 29 Apr 2021
A dividend of $0.24 per share was announced, adjusted to $0.24. The dividend was paid on 10 May 2021.
Earnings released on 31 Dec 2020
EPS came in at $0.60 surpassing the estimated $0.57 by +5.62%, while revenue for the quarter reached $4.56B , beating expectations by +10.11%.
0867.HK Stock Performance
Access detailed 0867.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.